Abbott Beats Q2 with $12.59B Revenue, Analysts Raise PT to $134; UNH Also Surges

In a robust week for healthcare earnings, both UnitedHealth Group (NYSE:UNH) and Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 results that handily beat Wall Street expectations, prompting a flurry of analyst target price hikes. The earnings beats underscored resilient demand across managed care and diversified medical products, while raised guidance signaled management confidence in sustaining momentum into the second half of the year. UnitedHealth posted adjusted earnings of $6.38 per share, obliterating the $4.86 consensus estimate by a staggering 31%, while revenue edged up to $112.03 billion from $111.62 billion a year earlier, exceeding the $110.83 billion forecast. CEO Stephen Hemsley attributed the strong performance to simplification efforts, improved affordability, and technology-driven enhancements to the healthcare experience. The company also raised its full-year 2026 earnings outlook, though specific revised figures were not immediately available. Abbott Laboratories, a diversified healthcare giant spanning medical devices, diagnostics, nutrition, and branded generic pharmaceuticals, reported adjusted EPS of $1.31, topping the $1.28 estimate. Revenue surged 13% year-over-year to $12.59 billion, comfortably ahead of the $12.50 billion consensus. On a comparable operational basis, sales grew 4.8%. Chairman and CEO Robert B. Ford said, 'Our second-quarter results reflect the momentum we are building... We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year.' Abbott raised its full-year adjusted EPS guidance to $5.45–$5.60 from $5.38–$5.58, bracketing the $5.49 consensus, and reaffirmed 6.5%–7.5% comparable sales growth for the year. Abbott also provided third-quarter adjusted EPS guidance of $1.38–$1.46, straddling the $1.42 consensus, indicating management’s confidence in near-term momentum. The beats triggered immediate analyst upgrades. For UnitedHealth, UBS analyst A.J. Rice raised the target to $490 from $460, RBC Capital’s Ben Hendrix upped to $478 from $463, and Truist’s David Macdonald boosted to $500 from $480—all retaining Buy/Outperform ratings. For Abbott, BTIG’s Marie Thibault lifted to $134 from $131, Evercore ISI’s Vijay Kumar raised to $120 from $112, while RBC’s Shagun Singh kept at $130. These adjustments reflect conviction that the earnings beats are not one-off but the start of sustained operational excellence. UnitedHealth’s outperformance was so pronounced that some analysts may revisit their models for the entire managed care group. UBS’s Rice noted that the company’s focus on technology and operational simplification is yielding tangible results, justifying a higher multiple. For Abbott, Evercore’s Kumar highlighted broad-based strength across segments, with particular strength in medical devices and diagnostics—areas that have benefited from an aging population and increased health awareness. Following the Thursday releases, UnitedHealth shares gained 1.3% to $428.75 on Friday, while Abbott edged 0.9% higher to $99.75 in pre-market trading. The price movements suggest the beats were partially priced in, but the magnitude of EPS surprises—especially UNH’s—reinforced investor confidence. From a macro perspective, the results come at a time when healthcare utilization is normalizing after pandemic distortions, and pricing power remains firm. Both companies’ ability to exceed expectations and raise guidance suggests they are adept at navigating cost inflation and labor shortages, which continue to challenge the broader economy. This earnings season may set a positive tone for the healthcare sector, especially if other large-cap names follow suit. The analyst upgrades also reflect a shift in sentiment: after months of caution regarding potential policy changes and Medicare reimbursement pressures, the strong fundamentals are compelling analysts to re-rate the stocks. For UnitedHealth, the new targets imply a forward P/E multiple in line with historical averages, but with higher earnings power. Abbott’s target upgrades suggest confidence in its pipeline of medical devices and diagnostics tests, which could drive above-market growth. In conclusion, the Q2 reports from UnitedHealth and Abbott demonstrate that healthcare bellwethers are not only weathering current challenges but thriving. With analysts swiftly raising forecasts, the market appears to be acknowledging that the sector’s defensive characteristics are coupled with genuine growth catalysts. Investors should monitor upcoming policy developments and the trajectory of medical utilization, but for now, the outlook is decidedly positive.